A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...

Daiichi Sankyo’s development of antibody-drug conjugates continues to hit turbulence. | Daiichi Sankyo’s development of ADCs ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

AstraZeneca & Daiichi Sankyo’s Datroway granted Priority Review in US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy: Cambridge ...

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

A single fecal microbiota transplantation from healthy donors increases the efficacy of immune checkpoint inhibition in both NSCLC and melanoma.

The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...

A new study published in the International Journal of Molecular Sciences by researchers from the Georgia Institute of Cannabis Research at Augusta University found that inhaling cannabidiol (CBD) ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...